Hossienizadeh Seyed Mohammad Javad, Bagheri Mohsen, Alizadeh Mahdi, Rahimi Masoud, Azimi Seyed Mahmoud, Kamalzade Morteza, Es-Haghi Ali, Ghassempour Alireza
Medicinal Plants and Drugs Research Institute, Shahid Beheshti University, G.C., Evin, Tehran, Iran.
Medicinal Plants and Drugs Research Institute, Shahid Beheshti University, G.C., Evin, Tehran, Iran; Department of Physico Chemistry, Razi Vaccine & Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), P.O. Box 31975/148 Karaj, Iran.
J Chromatogr A. 2021 Apr 26;1643:462070. doi: 10.1016/j.chroma.2021.462070. Epub 2021 Mar 15.
The production of high-quality purified virus particles in high quantities for vaccine preparation requires a scalable purification procedure in the downstream step. A purification scheme based on combined strong anion-exchange and size exclusion chromatography (2D-AEC-SEC) was developed for the production of non-structural protein-free foot and mouth disease vaccine, and the whole procedure was accomplished with 77.9% virus yield. Additionally, a mathematical modeling and a simulation approach based on a plate model of chromatography were developed and matched with the experimental chromatography data to improve prediction of retention behavior and save time in the development of the downstream scale-up method. The purified pooled virus fraction obtained from the final polishing step had a purity higher than 85% based on analytical size exclusion analysis. Moreover, more than 90.1% of residual DNA (rDNA) was removed from the purified vaccine. The analysis of purified virus particles by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), dynamic light scattering (DLS), high performance size exclusion chromatography (HP-SEC), matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), and transmission electron microscopy (TEM) provided clear evidence of purity and demonstrated that the final product is structurally spherical, intact particles qualified for formulation as a vaccine product.
为制备疫苗而大量生产高质量的纯化病毒颗粒需要在下游步骤中采用可扩展的纯化程序。开发了一种基于强阴离子交换和尺寸排阻色谱联用(二维阴离子交换色谱-尺寸排阻色谱,2D-AEC-SEC)的纯化方案,用于生产不含非结构蛋白的口蹄疫疫苗,整个过程的病毒回收率为77.9%。此外,还开发了一种基于色谱塔板模型的数学建模和模拟方法,并将其与实验色谱数据相匹配,以改进保留行为的预测,并节省下游放大方法开发的时间。基于分析型尺寸排阻分析,从最终精制步骤获得的纯化病毒合并组分的纯度高于85%。此外,从纯化疫苗中去除了超过90.1%的残留DNA(rDNA)。通过十二烷基硫酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)、动态光散射(DLS)、高效尺寸排阻色谱(HP-SEC)、基质辅助激光解吸/电离飞行时间质谱(MALDI-TOF MS)和透射电子显微镜(TEM)对纯化病毒颗粒进行分析,提供了纯度的明确证据,并证明最终产品在结构上是球形的完整颗粒,符合作为疫苗产品进行配方的要求。